Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $92.7 million.

  • Agios Pharmaceuticals' Cash & Equivalents fell 6346.12% to $92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year decrease of 6346.12%. This contributed to the annual value of $76.2 million for FY2024, which is 1355.71% down from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Cash & Equivalents stood at $92.7 million, which was down 6346.12% from $80.9 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Cash & Equivalents high stood at $1.9 billion for Q1 2021, and its period low was $64.3 million during Q3 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $92.7 million (2025), whereas its average is $264.1 million.
  • In the last 5 years, Agios Pharmaceuticals' Cash & Equivalents surged by 201916.2% in 2021 and then plummeted by 9576.14% in 2022.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Cash & Equivalents stood at $203.1 million in 2021, then tumbled by 31.44% to $139.3 million in 2022, then crashed by 36.66% to $88.2 million in 2023, then dropped by 13.56% to $76.2 million in 2024, then grew by 21.59% to $92.7 million in 2025.
  • Its last three reported values are $92.7 million in Q3 2025, $80.9 million for Q2 2025, and $79.0 million during Q1 2025.